For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient's gut microbiome can impact how effective the treatment is.

A recent study has revealed that the gut microbiome plays a critical role in tamoxifen’s metabolism, influencing its ...

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

Meta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half ...

Analyst Emily Bodnar of H.C. Wainwright reiterated a Buy rating on Atossa Therapeutics (ATOS – Research Report), retaining the price target of ...

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio of ...

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient’s gut microbiome can impact how effective the treatment is.